See more : Maverick Energy Group, Ltd. (MKGP) Income Statement Analysis – Financial Results
Complete financial analysis of Biocartis Group NV (BIOGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biocartis Group NV, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Priority Income Fund, Inc. (PRIF-PL) Income Statement Analysis – Financial Results
- Sega Sammy Holdings Inc. (SGAMY) Income Statement Analysis – Financial Results
- Woodbrook Group Holdings Inc. (WDBG) Income Statement Analysis – Financial Results
- Nang Kuang Pharmaceutical Co., Ltd. (1752.TW) Income Statement Analysis – Financial Results
- Seascape Energy Asia plc (SEA.L) Income Statement Analysis – Financial Results
Biocartis Group NV (BIOGF)
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 57.48M | 48.27M | 43.13M | 37.44M |
| Cost of Revenue | 29.80M | 33.92M | 26.28M | 21.33M |
| Gross Profit | 27.68M | 14.35M | 16.84M | 16.12M |
| Gross Profit Ratio | 48.16% | 29.72% | 39.06% | 43.04% |
| Research & Development | 38.39M | 48.05M | 40.93M | 39.84M |
| General & Administrative | 3.52M | 3.32M | 3.16M | 5.25M |
| Selling & Marketing | 5.05M | 3.08M | 3.38M | 4.56M |
| SG&A | 8.57M | 6.40M | 6.54M | 9.81M |
| Other Expenses | 27.47M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 74.43M | 76.65M | 63.23M | 71.46M |
| Cost & Expenses | 104.23M | 110.57M | 89.51M | 92.79M |
| Interest Income | 0.00 | 1.08M | 0.00 | 0.00 |
| Interest Expense | 11.19M | 9.32M | 10.18M | 7.10M |
| Depreciation & Amortization | 10.48M | 9.85M | 9.75M | 9.72M |
| EBITDA | -43.95M | -52.55M | -43.23M | -47.35M |
| EBITDA Ratio | -75.95% | -108.15% | -99.12% | -125.77% |
| Operating Income | -47.05M | -62.65M | -46.86M | -55.60M |
| Operating Income Ratio | -81.85% | -129.78% | -108.66% | -148.49% |
| Total Other Income/Expenses | -18.57M | -9.07M | -16.30M | -8.57M |
| Income Before Tax | -65.62M | -71.72M | -63.16M | -64.17M |
| Income Before Tax Ratio | -114.16% | -148.57% | -146.45% | -171.37% |
| Income Tax Expense | -240.00K | -243.00K | -228.00K | -99.00K |
| Net Income | -65.38M | -71.47M | -62.93M | -64.07M |
| Net Income Ratio | -113.74% | -148.07% | -145.92% | -171.10% |
| EPS | -1.08 | -1.24 | -1.11 | -1.14 |
| EPS Diluted | -1.08 | -1.24 | -1.11 | -1.14 |
| Weighted Avg Shares Out | 60.55M | 57.55M | 56.61M | 56.07M |
| Weighted Avg Shares Out (Dil) | 60.55M | 57.55M | 56.61M | 56.07M |
Source: https://incomestatements.info
Category: Stock Reports